Stage
No active trials
Next date
None yet
Trials
0 active
3 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer”In the company’s words, NCT05737485 on ClinicalTrials.gov
- Tested for
- Primary Ciliary Dyskinesia (2 trials), Primary Ciliary Dyskinesia (PCD)
- Main trialPhase 1
- “This is the first-in-human study with RCT1100 and is designed to provide initial safety and tolerability data for future clinical studies.”In the company’s words, NCT05737485 on ClinicalTrials.gov
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 25 Jul 2024 | Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects | |
| Phase 1Completed | 6 Jun 2025 | A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD | |
| Phase 1Completed | 30 Jun 2025 | Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026